Baidu
map

Meta分析软件—RevMan5.0使用中文指南(1)

2013-05-26 MedSci MedSci原创

Review Manager 5 Tutorial  RevMan5.0使用指南 前言 Welcome to the RevMan Tutorial. This tutorial is designed to give Cochrane review authors an introduction to the process of writing a Coch

Review Manager 5 Tutorial 
RevMan5.0使用指南

前言

Welcome to the RevMan Tutorial. This tutorial is designed to give Cochrane review authors an introduction to the process of writing a Cochrane systematic review of a healthcare intervention using RevMan. 
欢迎使用RevMan指南。这个指南指导Cochrane综述作者提供如何使用RevMan完成健康干预措施的系统综述。

The tutorial does not provide all the information necessary to write a Cochrane review, and does not address other types of Cochrane systematic reviews such as reviews of diagnostic test accuracy studies or overviews of reviews. For detailed instructions on how to conduct a Cochrane systematic review of an intervention, please refer to the Cochrane Handbook for Systematic Reviews of Interventions, available from the RevMan Help menu. 
这 个指南没有提供写一篇Cochrane综述所需的所有信息,也没有探讨其他类型研究的系统综述,如诊断精确性试验(diagnostic test accuracy studies)和综述的评价(overviews of reviews)。获取如何写一篇干预措施的Cochrane系统综述的更多信息,请参考RevMan帮助(Help)菜单下的“Cochrane Handbook for Systematic Reviews of Interventions”。

Later parts of this tutorial rely on activities completed in the earlier sections, so we recommend you start working from the beginning. If you would like to skip ahead, click on the section you would like to read in the Contents list. 
该使用指南的后面章节的内容是建立在前面章节基础上的,所以最好从开始看起。如果你不想看前面章节,在目录里点击你要看的章节。

If you have technical questions regarding RevMan software, please contact the Cochrane Information Management System team at www.cc-ims.net/RevMan. Other questions related to preparing protocols or reviews in RevMan should be directed to the relevant Cochrane Review Group. 
如 果有关于RevMan软件的技术问题,请在www.cc-ims.net/RevMan联系 Cochrane信息管理系统小组(Cochrane Information Management System team)。其他关于RevMan准备方案或综述的问题,请联系有关的Cochrane评价小组(Cochrane Review Group)。

Note: The results reported in this tutorial are fictional and were created by the authors. To find current information on the effects of an intervention, please refer to www.thecochranelibrary.com.
注意:该使用指南中报告的结果是假设的,数据由作者杜撰。查询目前有关一个干预措施效果的信息,请登录www.thecochranelibrary.com。

PART 1 – Getting started
第一章 开始综述

Opening your review
第一节 打开你的综述

Setting up user details 
第二节 设置用户信息

The RevMan 5 interface
第三节 RevMan 5 界面

Saving a review
第四节 保存综述

Adding authors to a review
第五节 添加综述的作者

Opening your review 
第一节 打开你的综述

All Cochrane reviews are stored in Archie, The Cochrane Collaboration’s online database. When you have registered a review with a Cochrane Review Group, they will set up a user account for you in Archie. To work on your review, you will need to find your review online in Archie and check it out into RevMan using the Check Out button on the toolbar. 
所 有的Cochrane综述都存在Cochrane协作组的网上数据库——Archie中。当你注册成为某个Cochrane综述小组(Cochrane Review Group)成员时,你会获得登录Archie的账户。为了开始你的综述,你需要在Archie数据库中找到你的综述,下载在RevMan中使用,完成后 再点击工具栏上的“Check Out”按钮上传综述。

For this tutorial we will use a sample review called ‘Caffeine for daytime drowsiness’. Instead of checking the review out of Archie, it has been provided as an additional file with RevMan 5. 
在本教程中,我们将使用名为“Caffeine for daytime drowsiness”的示例。它是RevMan 5 的附加文件,不需要从Archie中下载。

1. From the File menu, select Open, or click the Open button   on the toolbar. 
1 点击文件(File)菜单下的“Open”,或者点击工具栏上的“Open”按钮。

2. Find the folder where RevMan was installed on your computer. If you are using Windows and accepted the default installation location, this will be C:\\Program Files\Review Manager 5. 
2 找到RevMan在你的电脑中的安装目录。如果你使用的是Windows系统,默认安装目录为C:\\Program Files\Review Manager 5。

3. Open the doc folder, and then the tutorial folder. 
3 打开“doc”文件夹,然后打开“tutorial”文件夹。

4. Select the file ‘Caffeine for daytime drowsiness.rm5’. 
4 选择文件“Caffeine for daytime drowsiness.rm5”。

5. Click Open. 
5 点击“Open”。

Note: It is possible to create a new review in RevMan by selecting New from the File menu, or clicking the New button   on the toolbar. Be aware that if you create a review yourself, you cannot check it into Archie or use it for publication in The Cochrane Library. 
注意:在文件(File)菜单下选择“New”或点击工具栏上的“New”按钮,可在RevMan创建一个新的综述。注意,如果是你自己创建的综述,你就不能把它上传到Archie或者发表在Cochrane图书馆中。

Setting up user details 
第二节 设置用户信息

If you will be using RevMan regularly on the same computer, you may wish to enter your user details (such as your name). RevMan will attach these user details to any editing done using track changes so that co-authors and editors can easily identify who has made the changes. Open your user details by selecting Preferences from the Tools menu. Enter your name directly or click Choose to find your details in Archie. 
如 果你经常在同一台电脑上使用RevMan,你最好输入你的用户详细信息(比如,你的姓名)。在RevMan中,使用追踪改变(track changes)编辑功能时,你的信息会附在每个改变上,这样其他的共同作者就会清楚是谁作出的改变。在工具(Tools)菜单下选择 “Preferences”可以编辑你的用户信息。直接输入你的姓名或者点击“Choose”在Archie寻找你的用户信息。

Note: You will need to set up RevMan access to Archie via the internet. In the Preferences window, open the Connection tab. Click the Wizard button to set up your connection, or enter your Archie user name and password directly and click the Test button to check the connection. You may need to enter proxy server details. Consult the RevMan 5 Help or your local IT support for more information. 
注 意:RevMan需要网络连接才能连入Archie。在“Preferences”对话框,选择“Connection”选项卡。点击“Wizard”按 钮设置你的连接,或者在输入你的Archie用户名和密码后,点击“Test”按钮测试连接。你可能需要进行代理设置。获得更多信息,参考RevMan 5帮助文件,或者联系当地的IT提供商。

The RevMan 5 interface 
第三节 RevMan 5 界面

When a review is open in RevMan 5, you will see there are two separate window panes that interact with each other as you navigate through the different sections of a review. The pane on the left hand side shows the outline of a review. This is referred to as the outline pane. The area on the right hand side shows all the information contained in a review. This is referred to as the content pane. The content pane will usually show the text of your review, but can also contain additional tabs for results, figures, etc. 
当 一个综述在RevMan 5中打开后,当你浏览综述的不同部分时,会发现有两个相互联系但分离的窗口面板(window panes)。左边的面板显示综述的大纲。该面板称为大纲面板(outline pane)。右边的面板显示综述中的所有信息。该面板称为内容面板(content pane)。内容面板(content pane)通常显示综述的文本,但是也包括额外的标签页,如结果、图像等。

In the outline pane, you can use the key icon   next to each heading to expand and collapse subheadings. In the content pane, use the   symbol. 
在大纲面板(outline pane),你可以使用标题旁边的钥匙图标展开到子标题。在内容面板(content pane)中,则使用标题旁边的加号图标。

RevMan allows you to change the appearance of the interface by selecting Preferences from the Tools menu and going to the Interface tab. The default Look and Feel of the interface is Metal. All screen captures presented in this tutorial display the Metal look and feel. It is also possible to set language and spelling options in the Preferences window. 
你 可以在工具(Tools)菜单下“Preferences”的“Interface”选项卡中自定义RevMan的界面。默认的“Look and Feel”界面为“Metal”。本教程中的截图都是“Metal”主题。在“Preferences”中,你还可以选择语言以及拼写。

By default, your new review is at the protocol stage, indicating that you are planning the methods for a review. Sections of a review that are not required at the protocol stage (but will be needed later for your completed review) appear as inactive (light grey) in both the outline pane and the content pane. 
在 默认情况下,你的综述处于方案阶段(protocol stage),这说明你在为综述准备方法。一些综述部分在方案阶段(protocol stage)并不需要(但是,在完整的综述中时必需的),其在大纲面板(outline pane)和内容面板(content pane)中显示为撤销状态(浅灰)。

When you undertake a Cochrane review, the protocol must be completed and submitted for publication before moving on to the review stage. For this tutorial, to convert the file from the protocol stage to review stage, use the following directions: 
当你撰写Cochrane综述时,在综述阶段(review stage)前,你必须完成和提交方案。在本教程中,使用以下步骤,将综述从方案阶段(protocol stage)转为综述阶段(review stage):

1. Click the Properties button   in the top-right of the content pane. 
1 点击内容面板(content pane)右上角的“Properties”按钮。

2. In the Properties window, select the General tab. 
2 在“Properties”窗口中,选择“General”选项卡。

3. Note the automatically generated Version Number – this number will change each time the review is checked into Archie. Note that you do not need a separate Review Number unless your Review Group provides one. 
3 注意此时自动生成版本号(Version Number)——该号码在综述每次上传到Archie中后会改变。注意除非你的综述小组(Review Group)提供给你综述号(Review Number),你就不必填写该号码。

4. Enter the Version Description ‘First draft’. When choosing a version description, make sure it is brief and clearly indicates what’s different about this draft, e.g. ‘Edited by [your initials]’ or ‘Methods section complete’. 
4 在“Version Description”中输入“First draft”。在选择版本描述(version description)时,请确认使用简短而清楚的话说明该版本有什么改变,比如“Edited by [your initials]” 或 “Methods section complete”。

5. For the Stage, select Full Review. 
5 在“Stage”,选择“Full Review”。

6. Click OK. Note that all of the section headings of the review are now activated for inclusion (there are no light grey section headings).
6 点击“OK”。注意综述的部分标题(section headings)被纳入激活了(不再存在浅灰的部分标题)。

Saving a review 
第四节 保存综述

When you have finished working on a review from Archie, we recommend that you always save the review by checking it back into Archie using the Check In   button on the toolbar. This ensures the most recent version of your review is safely stored and can always be accessed from Archie by your co-authors and editors. 
当你完成从Archie下载下来的综述后,最好使用工具栏上“Check In”按钮将其上传回Archie。这样可以保证你的综述的最新版本被安全地保存,其他共同作者和编辑也可以从Archie下载该综述。

We recommend that you do not keep saved reviews on your computer, to avoid confusion with different versions. Be careful not to use a version of your review from your computer if a more recent version is available in Archie. If for some reason you do need to save a review to your computer, such as this tutorial review which is not from Archie, go to the File menu and select Save As, or click the Save   button on the toolbar. You can open a saved review by going to the File menu and selecting Open, or clicking the Open button   on the toolbar.  
我 们不建议你把综述保存在你的电脑中,一面发生版本混乱。记住如果可以从Archie获得最新的版本,就不要使用你电脑中的版本。在某些情况下,你必须把综 述存在你的电脑中,比如,该教程的综述不是来自Archie,点击文件(File)菜单下的“Save As”,或者点击工具栏上的“Save”按钮。如果要打开一个已保存的文件,点击点击文件(File)菜单下的“Open”,或者点击工具栏上的 “Open”按钮。

RevMan also creates automatic backups of your review. See the Help menu for information on retrieving a backup file. 
RevMan会自动创建综述的备份。查看帮助(Help)菜单,获得如何恢复备份文件的相关信息。

Adding authors to a review 
第五节 添加综述的作者

For a real review, your Review Group will add your name as an author of the review when they create the file, along with any known co-authors. You may wish to add additional authors later. 
在真实的综述中,你的综述小组(Review Group)在创建综述时,会把你的名字和其他已知共同作者的名字添加为综述的作者。但是,你也许会增加额外的作者。

There are two ways to add authors to a review: 
在一个综述中添加作者有两种方法:

•  Add an author based on their record in Archie – this option allows you to add authors who are already listed in the Archie database. You will need to have internet access and an Archie user account for this option. 
   基于Archie中的记录创建——这允许你添加Archie数据库中已有的作者。你需要网路连接和Archie账户来进行此项操作。

•  Add a local record (name only) that can be linked to Archie later – this option allows you to add authors that are not yet listed in Archie. 
   在本地创建作者(只有姓名),随后链接到Archie——这个操作允许你添加Archie中没有的作者。

1. In the content pane, click the   icon next to the Review information heading to show further subheadings. 
1 在内容面板(content pane),点击“Review information”左边的加号图标展开子标题。

2. Click the   icon to open the Authors section. Note that three authors have already been added to this review. 
2 点击加号图标展开“Authors”部分。注意在本综述,已有三个作者。

3. In the outline pane, click the key icon   next to Review information. 
3 在大纲面板(outline pane),点击点击“Review information”旁边的钥匙图标。

4. Select the Authors heading. 
4 选择““Authors”标题。

5. Click the Add Author   button on the outline pane toolbar to open the New Author Wizard. 
5 点击大纲面板工具栏(outline pane toolbar )上的“Add Author”按钮,打开“New Author Wizard”对话框。

6. Select Add a local record (name only) that can be linked to Archie later. Click Next. 
6 选择“Add a local record (name only) that can be linked to Archie later”,点击下一步(Next)。

7. Enter your name in the First Name and Family Name fields. 
7 输入你的姓名。

8. Click Finish. You will now see your name listed next to the other authors of the review. Note that no affiliation is available for your name. Affiliations can only be added from records in Archie. 
8 点击完成(Finish)。你的名字和综述的其他作者列在一起了。注意你的名字下没有工作单位,工作单位只有来自Archie记录的作者才有。

Under the author details in both the outline and content panes you will note that a Contact person can be specified for the review. By default, this is the first author, but another person (who may or may not be an author of the review) can be nominated by selecting the Contact person heading in the outline pane and clicking the Edit Contact Person   button on the outline pane toolbar. The contact person must be listed in Archie. 
在 大纲和内容面板(outline and content panes)下的作者细节,你会发现可以给综述添加特定的通讯作者( Contact person)。通常,这个作者为第一作者,但是其他作者(可能是或不是综述作者)也能作为通讯作者( Contact person)。选择大纲面板(outline pane)中的“Contact person”标题,点击大纲面板工具栏(outline pane toolbar )上的“Edit Contact Person”按钮,即可推荐通讯作者( Contact person)。通讯作者( Contact person)只能是Archie中已有的作者。

Note: To add new people to Archie or to make changes to contact details, please contact your Review Group Co-ordinator. 
注意:在Archie中添加新作者或者改变已有作者的信息,请联系你所在综述小组(Review Group)协调员。

更多
Meta分析软件—RevMan5.0使用中文指南(1)
Meta分析软件—RevMan5.0使用中文指南(2)
Meta分析软件—RevMan5.0使用中文指南(3)
Meta分析软件—RevMan5.0使用中文指南(4)
Meta分析软件—RevMan5.0使用中文指南(5)
Meta分析软件—RevMan5.0使用中文指南(6)

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]
    2016-01-01 木醇阳

    好的

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]
    2015-12-10 oo

    实用

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]
    2015-11-28 1de00086m73(暂无匿称)

    实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]
    2015-11-26 老段

    不会

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]
    2014-11-16 cmdcro

    生手,下不了啊

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]
    2014-04-24 guojianrong
  7. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]
    2013-08-09 一闲
  8. [GetPortalCommentsPageByObjectIdResponse(id=50914, encodeId=24a2509148f, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20151027/IMG562EB376ED6788263.jpg, createdBy=e6ea1659259, createdName=木醇阳, createdTime=Fri Jan 01 09:17:00 CST 2016, time=2016-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=45411, encodeId=066e4541194, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=156, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/03/05/4b2b388f99aa91ab444d692709b0ffd1.jpg, createdBy=b3a41667394, createdName=oo, createdTime=Thu Dec 10 05:50:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44041, encodeId=3fe844041c8, content=实用, beContent=null, objectType=article, channel=null, level=null, likeNumber=150, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/Pw2csslt7CukWiabqiblnQAbAss3ANsjUWZKUgN2n3JyJDHOJJAxibetNCiaEh70YckbPPTELyyStMZ8T3Q340icNSXgj72MowgTC/0, createdBy=188f1666747, createdName=1de00086m73(暂无匿称), createdTime=Sat Nov 28 22:36:00 CST 2015, time=2015-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=43925, encodeId=956d4392533, content=不会, beContent=null, objectType=article, channel=null, level=null, likeNumber=158, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Nov 26 21:04:00 CST 2015, time=2015-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=12527, encodeId=a5911252e0b, content=生手,下不了啊, beContent=null, objectType=article, channel=null, level=null, likeNumber=233, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a5c1606100, createdName=cmdcro, createdTime=Sun Nov 16 13:24:00 CST 2014, time=2014-11-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1887345, encodeId=3d47188e34537, content=<a href='/topic/show?id=d56611584ec' target=_blank style='color:#2F92EE;'>#Meta#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11584, encryptionId=d56611584ec, topicName=Meta)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d8f4110, createdName=guojianrong, createdTime=Thu Apr 24 22:58:00 CST 2014, time=2014-04-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1895663, encodeId=a9c71895663b4, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Aug 09 09:58:00 CST 2013, time=2013-08-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250165, encodeId=124b12501652e, content=<a href='/topic/show?id=2ec715405f6' target=_blank style='color:#2F92EE;'>#RevMan#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15405, encryptionId=2ec715405f6, topicName=RevMan)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=杏林小小, createdTime=Sun May 26 23:58:00 CST 2013, time=2013-05-26, status=1, ipAttribution=)]

相关资讯

Review Manager(RevMan)4.2软件教程(中文版)及软件下载

RevMan软件是国际Cochrane协作网制作和保存Cochrane系统评价的一个程序,是最常用的循证医学中作系统评价和分析的软件。由北欧Cochrane中心制作和更新。协作网的系统评价人员均使用RevMan软件制作系统评价。该软件的主要特点是可以制作和保存Cochrane系统评价的计划书和全文;可对录入的数据进行Meta分析并以森林图(forest plot)的图表形式展示;可对Co

Baidu
map
Baidu
map
Baidu
map